Clinical trial NCT06797427: A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
Official title: An Open-label, Prospective, Randomised, Cross-over Trial to Assess the Pharmacokinetics of an Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: PK study
Sorafenib
Hepatocellular carcinoma
MMC
Amorphous formulation
Mesoporous magnesium carbonate
Absorption
Bioavailability
Drug delivery
Kinase inhibitors
Lead sponsor: Disruptive Pharma
Sponsor class: INDUSTRY
Collaborators: name: CTC Clinical Trial Consultants AB
First posted: 2025-01-28
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.

Detailed description: This is an open-label, prospective, randomized, cross-over, single-center trial designed to evaluate the bioavailability, safety, and tolerability of DPH001 compared to Nexavar® in healthy male participants and healthy female participants of non-childbearing potential. The objective of the study is to compare the pharmacokinetics (PK) of sorafenib after the administration of 100 mg DPH001 vs. after the administration of 200 mg Nexavar®. After being informed of the study and potential risks, all subjects given written informed consent will undergo a screening to determine eligibility for study entry. Participants will receive, in a randomized order, 1 dose of 100 mg DPH001, and 1 dose of 200 mg Nexavar®, all in a fasted state. IMP administrations will be separated by wash-out periods of at least 14 days.

Eligibility criteria: Inclusion Criteria:

1. Willing and able to give written informed consent for participation in the trial, including consenting to the planned restrictions during the trial.
2. Healthy male or female participant aged 18 to 65 years, inclusive.
3. Body mass index (BMI) ≥18.5 and ≤30.0 kg/m2 at the time of the screening visit.
4. Medically healthy participant without abnormal clinically significant medical/surgical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.
5. Female trial participants: Only female participants of non-childbearing potential will be considered eligible for participation. Female participants of non-childbearing potential are defined as:

   * pre menopausal females who have undergone hysterectomy and/or bilateral salpingectomy and/or bilateral oophorectomy,
   * post menopausal females, defined as having undergone at least 12 months of amenorrhea. In questionable cases a blood sample with detection of follicle stimulating hormone (FSH) \>25 IU/L will be confirmatory.

Male trial participants: Male participants must be willing to use condoms during sexual intercourse to prevent pregnancy and/or the drug exposure of a partner from the first IMP administration at Visit 2 and until 3 months after the last IMP administration at Visit 12.

In addition, any female partner of a male participant who is of childbearing potential must use contraceptive methods with a failure rate of \<1%/year to prevent pregnancy from at least 2 weeks prior to the first administration of IMP to 3 months after the last administration of IMP.

The following are considered highly effective methods of contraception:

* combined (oestrogen and progestogen-containing) or progestogen-only hormonal contraception associated with the inhibition of ovulation (oral, transdermal, intravaginal, injectable, or implantable),
* intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the results or the participant's ability to participate in the trial.
2. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the (first) administration of IMP.
3. Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.
4. Any planned major surgery within the duration of the trial.
5. Any positive result at the screening visit for serum hepatitis B surface antigen, hepatitis C antibodies and/or HIV antigen and antibodies.
6. After 10 minutes supine rest at the screening visit, any vital signs values outside the following ranges:

   * systolic blood pressure: \<90 or ≥140 mmHg, or
   * diastolic blood pressure \<50 or ≥90 mmHg, or
   * pulse \<40 or ≥90 bpm.
7. A mean QTcF interval of ≥450 ms at screening or a family history of long QT syndrome, as judged by the Investigator.
8. Abnormal ECG morphology at screening, including abnormality in PR and/or QRS intervals, as well as signs of bundle branch block (BBB), as judged by the Investigator.
9. History of cardiac arrhythmias or palpitations, including ectopic heart beats and/or extra systoles (premature ventricular contractions), as judged by the Investigator.
10. Hepatic dysfunction, defined as serum transaminase (aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\]) levels above the upper limit of normal (ULN) at screening, if considered clinically significant by the Investigator.
11. Any other clinically relevant abnormalities in clinical chemistry, haematology, and coagulation parameters from safety laboratory tests at screening, at the discretion of the Investigator.
12. History of severe reaction, including allergy/hypersensitivity, to drugs with a similar chemical structure, class, or mechanism of action to sorafenib, and/or reaction to any drug that led to significant morbidity, as judged by the Investigator.
13. History of or ongoing major depressive disorder (MDD) and/or any history of suicidal ideation (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent), at the discretion of the Investigator.
14. Regular use of any prescribed or non-prescribed medications, at the discretion of the Investigator, including antacids, analgesics, antibiotics, anticoagulants, non-steroidal anti-inflammatory drugs, herbal remedies, vitamins, and mineral, within 2 weeks prior to the first planned IMP administration at Visit 2, except the following:

    * Prescribed and stable treatment with any hormone replacement therapy (HRT).
    * Occasional intake of paracetamol (maximum 2000 mg/day for a maximum of 3 consecutive days and not exceeding 3000 mg/week).
    * Nasal decongestants without cortisone, antihistamine, or anticholinergics for a maximum of 10 days.
15. Planned treatment or treatment with another investigational drug within 3 months prior to Visit 2. Participants consented and screened but not dosed in previous phase I trials will not be excluded.
16. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week before the screening visit will be allowed.
17. Positive test result for drugs of abuse or alcohol at screening.
18. History or manifestation at screening of drug abuse, alcohol abuse and/or excessive intake of alcohol, as judged by the Investigator.
19. History of, or current use, of anabolic steroids, as judged by the Investigator.
20. Excessive caffeine consumption defined by a daily intake of \>5 cups (1 cup = approximately 240 mL) of caffeine-containing beverages, as judged by the Investigator.
21. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening.
22. The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.

Primary outcomes:
measure: To compare the AUC (0-6h) of sorafenib after the administration of 100 mg DPH001 vs. 200 mg Nexavar® in fasted conditions.
timeFrame: From administration of study drug until 4 days
measure: To compare the AUC (0-72 h) of sorafenib after the administration of 100 mg DPH001 vs. 200 mg Nexavar® in fasted conditions.
timeFrame: From administration of study drug until 4 days
measure: To compare the AUC (inf) of sorafenib after the administration of 100 mg DPH001 vs. 200 mg Nexavar® in fasted conditions.
timeFrame: From administration of study drug until 4 days
measure: To compare the Cmax of sorafenib after the administration of 100 mg DPH001 vs. 200 mg Nexavar® in fasted conditions.
timeFrame: From administration of study drug until 4 days
measure: To compare the Tmax of sorafenib after the administration of 100 mg DPH001 vs. 200 mg Nexavar® in fasted conditions.
timeFrame: From administration of study drug until 4 days
Secondary outcomes:
measure: Number of subjects with treatment-related adverse events assessed by frequency.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with treatment-related adverse events assessed by seriouness.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with treatment-related adverse events assessed by intensity.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with treatment-related adverse events assessed by relationship to study treatment.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the systolic blood pressure.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the diastolic blood pressure.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the ECG parameter QRS.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the ECG parameter QT.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the ECG parameter PQ/PR.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the ECG parameter QTcF.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the ECG parameter heart rate.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the clinical chemistry parameters.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the hematology parameters.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the coagulation parameters.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the head.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the eyes.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the ears.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the nose.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the throat.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the skin.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the thyroid.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the neurological.
timeFrame: From administration of study drug end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the lungs.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the cardiovascular.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the abdomen (liver and spleen).
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the lymphnodes.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with a clinical significant change from baseline in the physical examination of the extremities.
timeFrame: From administration of study drug until end of trial (period 2 day 8).
measure: Number of subjects with treatment-related adverse events assessed by frequency.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with treatment-related adverse events assessed by seriouness.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with treatment-related adverse events assessed by intensity.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with treatment-related adverse events assessed by relationship to study treatment.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with a clinical significant change from baseline in the clinical chemistry parameters.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with a clinical significant change from baseline in the hematology parameters.
timeFrame: From administration of study drug until 72 hours.
measure: Number of subjects with a clinical significant change from baseline in the coagulation parameters.
timeFrame: From administration of study drug until 72 hours.
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Clinical Trial Consultants (CTC), Dag Hammarskjölds väg 10B
Study officials:
affiliation: Clinical Trial Consultants (CTC), Dag Hammarskjölds väg 10B, 752 37 Uppsala, Sweden
name: Björn Schultze, MD
role: PRINCIPAL_INVESTIGATOR
References: